Immunomedics Reports First Results From Phase Ib Study of 90Y-Clivatuzumab in Patients With Metastatic Pancreatic Cancer After 2

Immunomedics Reports First Results From Phase Ib Study of 90Y-Clivatuzumab in
Patients With Metastatic Pancreatic Cancer After 2 or More Prior Therapies

  -- Repeated Cycles of ^90Y-Clivatuzumab Treatments Extended Survival When
                         Compared to Single Cycle--

 -- Low-Dose Gemcitabine in Combination with ^90Y-Clivatuzumab Significantly
                  Improved Efficacy of Treatment Regimen--

             -- Company Planning Phase III Registration Trial --

BARCELONA, Spain, July 3, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc.
(Nasdaq:IMMU), a biopharmaceutical company primarily focused on the
development of monoclonal antibody-based products for the targeted treatment
of cancer, autoimmune and other serious diseases, today announced encouraging
results from the Phase Ib study with clivatuzumab labeled with the
radioisotope, yttrium-90 (^90Y), in patients with metastatic pancreatic cancer
who had received at least 2 prior treatments. Results from this trial were
reported by Edith Mitchell, MD, from the Kimmel Cancer Center of Thomas
Jefferson University in Philadelphia, PA, in an oral presentation at the
European Society for Medical Oncology (ESMO) 15^th World Congress on
Gastrointestinal Cancer.

Clivatuzumab is a humanized antibody developed by the Company for the
treatment of pancreatic cancer. It targets a specific tumor marker produced by
almost all pancreatic cancers that is not usually present in pancreatitis,
normal pancreas or most other normal tissues. The Company has previously
reported a median overall survival (OS) of 11.8 months in patients with newly
diagnosed, untreated, advanced pancreatic cancer after receiving repeated
cycles of the ^90Y-labeled antibody in combination with low-dose

The current Phase Ib study of clivatuzumab was undertaken in pancreatic cancer
patients with two or more prior therapies. For these relapsed patients, there
is no agreed standard-of-care, and options for further therapy are limited.
Clivatuzumab may offer an attractive alternative, especially for those
patients with adequate performance status who are unable or unwilling to
accept the side effects of additional chemotherapy. The objective of this
multicenter trial was to evaluate the safety, tolerability, and evidence of
efficacy of the ^90Y-labeled-clivatuzumab treatment regimen in
previously-treated patients with metastatic pancreatic cancer, and to
determine the contribution of low-dose gemcitabine to the treatment regimen.

A total of 58 patients were randomized to receive either
^90Y-labeled-clivatuzumab once-a-week for 3 weeks at 6.5 mCi/m^2 with
gemcitabine 200 mg/m^2 given weekly x 4 weeks (Arm A) or
^90Y-labeled-clivatuzumab alone (Arm B). This treatment cycle was repeated
every 4 weeks until unacceptable toxicity, patient deterioration or patient
withdrawal. Patients were followed for one year or until death. The median age
of these patients was 65, with a median of 1.6 years from initial diagnosis,
and a median of 3 (2-6) prior treatments.

Results from 53 patients who completed at least one treatment cycle were
presented. The median overall survival (OS) for Arm A
(^90Y-labeled-clivatuzumab with low-dose gemcitabine, N=27) was 119 days, a
significant improvement over Arm B (^90Y-labeled-clivatuzumab alone, N=26),
with a median OS of 80 days (P=0.04). Furthermore, for the 23 patients who
received multiple cycles of therapy, the median OS increased to 157 days in
Arm A compared with 103 days in Arm B.

Survival was also related to patients' Karnofsky Performance Status (KPS)
scores at study entry, increasing from a median of 79 days for patients with
80% KPS to 119 days for patients with 90-100% KPS. In contrast, increased
number of prior treatments is a negative prognostic indicator for survival.
The median OS decreased from 90 to 82 to 73 days for patients who received 2,
3, or 4-5 prior treatments, respectively.

"We are very encouraged with these results, and we believe this study
demonstrated the feasibility of conducting clinical trials in pancreatic
cancer patients relapsed to 2 or more prior treatments. We have made the
strategic decision to move forward with a Phase III clinical trial,
positioning clivatuzumab in this setting as a therapy for patients with
advanced pancreatic cancer who have few to no treatment options," remarked
Cynthia L. Sullivan, President and Chief Executive Officer. "We have designed
and vetted our protocol with key opinion leaders and FDA, selected our
clinical research organization, and plan to enroll the first patient into the
Phase III clinical trial by the end of this calendar year, or the beginning of
2014. Most of our clinical trial sites will be in the US, with some additional
sites in the EU," Ms. Sullivan added. "For future clinical trials, KPS and
number of prior treatments will be considered as important survival
prognosticators," concluded Ms. Sullivan.

Based on the 2013 Cancer Facts and Figures report by the American Cancer
Society, an estimated 45,220 Americans will be diagnosed with pancreatic
cancer in 2013, making it the 10^th most common cancer diagnosis among men and
the 9^th most common among women in the U.S. It is, however, the fourth
leading cause of cancer death among both men and women nationwide, with
approximately 38,460 deaths expected, or about 7% of all cancer deaths.

The outlook for pancreatic cancer patients is bleak, with median survival
ranges from 4.5 months for the most advanced stage to 24.1 months for the
earliest stage. For patients with the advanced disease, treatment options are
limited to gemcitabine alone or in combination with other agents. Although
FOLFIRINOX, the drug combination of leucovorin, fluorouracil, irinotecan, and
oxaliplatin, has recently been shown to prolong survival in patients with
newly-diagnosed advanced disease, many patients could not tolerate this
treatment regimen.


1. Ocean A.J., Pennington K.L., Guarino M.J., Sheikh A., Bekaii-Saab T.,
Serafini A.N., Lee D., Sung M.W., Gulec S.A., Goldsmith S.J., Manzone T., Holt
M., O'Neil B.H., Hall N., Montero A.J., Kauh J., Gold D.V., Horne H., Wegener
W.A., Goldenberg D.M. Fractionated radioimmunotherapy with (90) Y-clivatuzumab
tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A
phase 1 trial. Cancer. 2012 Nov 15;118(22):5497-506. doi: 10.1002/cncr.27592.
Epub 2012 May 8.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused
on the development of monoclonal antibody-based products for the targeted
treatment of cancer, autoimmune and other serious diseases.We have developed
a number of advanced proprietary technologies that allow us to create
humanized antibodies that can be used either alone in unlabeled or "naked"
form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or
toxins, in each case to create highly targeted agents.Using these
technologies, we have built a pipeline of therapeutic product candidates that
utilize several different mechanisms of action.We also have a majority
ownership in IBC Pharmaceuticals, Inc., which is developing a novel
DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and
multifunctional antibodies, and a new method of delivering imaging and
therapeutic agents selectively to disease, especially different solid cancers
(colorectal, lung, pancreas, etc.), by proprietary, antibody-based,
pretargeting methods. We believe that our portfolio of intellectual property,
which includes approximately 223 active patents in the United States and more
than 400 foreign patents, protects our product candidates and
technologies.Our strength in intellectual property has resulted in the top-10
ranking in the 2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology
and Pharmaceuticals category.For additional information on us, please visit
our website at The information on our website does not,
however, form a part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials, out-licensing arrangements (including the timing and amount of
contingent payments), forecasts of future operating results, potential
collaborations, and capital raising activities, involve significant risks and
uncertainties and actual results could differ materially from those expressed
or implied herein. Factors that could cause such differences include, but are
not limited to, risks associated with any cash payment that the Company might
receive in connection with a sublicense involving a third party and UCB, which
is not within the Company's control, new product development (including
clinical trials outcome and regulatory requirements/actions), our dependence
on our licensing partners for the further development of epratuzumab and
veltuzumab for non-cancer indications, competitive risks to marketed products
and availability of required financing and other sources of funds on
acceptable terms, if at all, as well as the risks discussed in the Company's
filings with the Securities and Exchange Commission.The Company is not under
any obligation, and the Company expressly disclaims any obligation, to update
or alter any forward-looking statements, whether as a result of new
information, future events or otherwise.

CONTACT: Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
Press spacebar to pause and continue. Press esc to stop.